Sionna Therapeutics, Inc.
HealthcareNASDAQ:SION · NASDAQ Global Market
-$0.13 today
Vol 0.19M · Avg 0.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.5%
avg 28.0%
ROIC
-28.2%
avg -58.3%
ROA
-23.1%
avg -48.3%
Analysis
ROA is currently the strongest return metric at -23.1% versus its period average of -48.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Cloonan | President, Chief Executive Officer & Director | $1.03M | — | 54 | $436,100.00 | 0.97% |
Elena H. Ridloff | Chief Financial Officer | $771,602.00 | — | 46 | $165,440.00 | 0.37% |
Charlotte McKee | Chief Medical Officer | $647,922.00 | — | 61 | $155,700.00 | 0.34% |
Caroline Stark Beer | Chief Business Officer | $268,113.00 | — | 47 | $139,340.00 | 0.31% |
Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research | — | — | — | — | — |
Mark Munson | Co-founder & Senior Vice President of Medicinal Chemistry | — | — | — | — | — |
Andy Chu | Vice President of Information & Technology | — | — | — | — | — |
Kenneth A. Lock | Chief Commercial Officer | — | — | 52 | $2.67M | 5.92% |
Jennifer Fitzpatrick | Chief Legal Officer | — | — | 49 | $50,935.00 | 0.11% |
Mara Furlow | Senior Vice President of Global Regulatory Affairs & Quality | — | — | — | — | — |
Meghan Bagshaw | Vice President of Programs, Portfolio & Operations | — | — | — | — | — |
Sarah J. Spencer | Vice President of Corporate Communications | — | — | — | — | — |
Vanya Sagar | Chief People Officer | — | — | 50 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$950,400.00
Sells
153
$155.94M
Net Sentiment
$154.99M
Net selling
Most Active
Booth Bruce
50 transactions
1–10 of 154
Analysis
Insiders reported 1 buys worth $950,400.00 and 153 sells worth $155.94M over the last 12 months. That adds up to net selling of $154.99M. Booth Bruce was the most active insider with 50 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages SION?
Sionna Therapeutics, Inc. (SION) lists 13 active executives. The top listed executive is Charlotte McKee, Chief Medical Officer.
Are SION insiders buying or selling?
Recent insider activity shows net selling of $105.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.